Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01580969 · ClinicalTrials.gov registry record · Phase 1
Repeat Radiation, Minocycline and Bevacizumab in Patients With Recurrent Glioma
A Phase 1 study, sponsored by University of Utah.
- Completed
- Registry status
- Phase 1
- Development phase
- 22
- Enrollment target
NCT01580969 is a Phase 1 study that has completed, run by University of Utah. The registered enrollment target is 22 participants.
The verdict
NCT01580969, a Phase 1 study, has completed, sponsored by University of Utah.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 22 participants
- Enrollment target
Study Summary
The primary objective of step 1 is the rate of adverse events of minocycline and bevacizumab during reirradiation and of step 2 is the response rate to bevacizumab, reirradiation, and minocycline. The secondary objectives are the response rate, Progression Free Survival (PFS)-3, PFS-6, and effects on quality of life and cognition from repeat radiation and bevacizumab.
Interventions
- DRUG Bevacizumab
- RADIATION Radiation
- DRUG Minocycline
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 22 participants |
| Start Date | 2012-07-06 |
| Est. Completion | 2018-05-15 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01580969
The ClinicalTrials.gov registry entry for NCT01580969 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 22 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Utah, which has 818 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Bevacizumab is the first listed.
NCT01580969 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01580969 about?
NCT01580969 is a clinical study titled "Repeat Radiation, Minocycline and Bevacizumab in Patients With Recurrent Glioma". The primary objective of step 1 is the rate of adverse events of minocycline and bevacizumab during reirradiation and of step 2 is the response rate to bevacizumab, reirradiation, and minocycline. The secondary objectives are the response rate, Progression Free Survival (PFS)-3, PFS-6, and effects o...
What is the current status of trial NCT01580969?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 22 participants. The study started on 2012-07-06. Estimated completion is 2018-05-15.
What interventions are being tested in trial NCT01580969?
The interventions under investigation include: Bevacizumab (DRUG), Radiation (RADIATION), Minocycline (DRUG).
Who is sponsoring clinical trial NCT01580969?
This trial is sponsored by University of Utah, which has 818 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.